- Home
- BEP vs ABVX Comparison
BEP vs ABVX Comparison
Compare BEP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BEP | ABVX |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BEP | ABVX |
|---|---|---|
| Price | $28.08 | $119.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $34.00 | ★ $130.09 |
| AVG Volume (30 Days) | 456.9K | ★ 2.1M |
| Earning Date | 01-30-2026 | 08-11-2025 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,300,000,000.00 | $6,231,374.00 |
| Revenue This Year | $6.98 | $6.80 |
| Revenue Next Year | $7.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $19.29 | $4.77 |
| 52 Week High | $32.72 | $148.83 |
Technical Indicators
Market Signals| Indicator | BEP | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 47.95 |
| Support Level | $27.48 | $113.64 |
| Resistance Level | $28.52 | $122.50 |
| Average True Range (ATR) | 0.73 | 8.73 |
| MACD | 0.10 | -1.40 |
| Stochastic Oscillator | 64.63 | 36.25 |
Price Performance
Historical ComparisonAbout BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.